Sponsored Content for Roger Aston

ASX-listed PharmAust continues to receive positive news from the ongoing Phase IIb trial of its “Monepantel” anti-cancer drug trial on dogs. The clinical-stage oncology company said the interim analysis of its drug trial provided further supportive evidence of the blood plasma levels of the Monepantel drug required to suppress B-cell lymphoma growth in pet owner's dogs.

ASX-listed clinical-stage oncology group, PharmAust, has taken the next significant step towards establishing whether its cancer fighting drug, Monepantel, can also inhibit COVID-19. The Perth-based company has struck an agreement with an internationally renowned biomedical research university in the Netherlands that will examine the suitability of Monepantel and Monepantel Sulfone for the all-important preclinical ex-vivo stage of testing that precedes the critical clinical trials.

ASX-listed clinical-stage oncology group, PharmAust, continues to show that its cancer fighting drugs, Monepantel and Monepantel Sulfone, can have a positive, anti-viral effect on cultured cells that are infected with the Coronavirus. According to the Perth-based company, a second repeat of its in-vitro anti-viral confirmatory testing successfully demonstrated the anti-COVID-19 activity of both Monepantel and Monepantel Sulfone.

PharmAust's cancer fighting drugs continue to inhibit COVID-19 in its testing of the effects of the drugs on cultured cells infected by the virus. Preliminary results from lab studies undertaken for PharmAust by the Walter and Eliza Hall Institute of Medical Research in Melbourne show the virus can be suppressed by up to about 95 per cent following treatment with the company's monepantel and monepantel sulfone products.

ASX-listed PharmAust Limited has shown that the initial successful testing of its cancer fighting drug, Monepantel, against the COVID-19 virus may not have been a fluke, with new testing showing a “remarkable” 95% suppression rate in the infectivity of the SARS-CoV- 2 virus (COVID-19) in laboratory tests by both Monepantel and Monepantel sulfone. Testing was undertaken at Walter and Eliza Hall Institute of Medical Research in Melbourne.

ASX-listed PharmAust Limited has chalked up a remarkable success with its rapidly developing “Monepantel” anti-cancer drug after its latest trial on man's best friend showed a significant turnaround in the health of dogs suffering from naïve B cell lymphoma. One dog achieved greater than 60 per cent reduction in tumour burden, with one of its tumours regressing completely.

ASX-listed PharmAust Limited will shortly commence laboratory testing of the effects of its anti-cancer drug, Monepantel on the Coronavirus after entering into an agreement with the Walter and Eliza Hall Institute of Medical Research in Melbourne, Victoria. The study will be overseen by the Institute's award-winning, chronic infections researcher, Professor Marc Pellegrini, with feedback expected as early as May this year.

ASX-listed PharmAust's innovative biotechnology work via its wholly owned subsidiaries Epichem and Pitney Pharmaceuticals has been recognised by the Australian Tax Office with the company receiving more than $700,000 in a research and development tax rebate. The funds will be used to advance its clinical trial programs in dogs and humans with the company now on a fast tracked pathway to prove up the cancer fighting abilities of its “re-purposed” Monepantel drug.

ASX listed biotech, PharmAust, has been awarded a one-year extension to its contract with not for profit organization, the Drugs for Neglected Diseases Initiative, which commemorates the 12th-year of association between the two parties. Under the contract, which is expected to bring in $1.24m in revenue, PharmAust's subsidiary, Epichem, will provide synthetic and medicinal chemistry services focused on developing new treatments for neglected diseases.

ASX-listed PharmAust's fully-owned subsidiary, Epichem, has appointed experienced pharmaceutical and healthcare executive, Colin La Galia, as its new CEO and he will replace Dr Martine Keenan, who will step down from the role to resume her former position as Epichem Head of Drug Discovery and join the company's board. Epichem is a successful contract medicinal chemistry company that is forecasting $4.2m revenues for the current financial year.

Epichem, a subsidiary of ASX-listed biotech, PharmAust, has been rewarded for its contribution to WA and nominated as the year's winner of the prestigious WA Industry and Export Awards. The company was acknowledged for its contributions to the global health and biotechnology sector by providing “end-to-end” support in drug discovery, with CEO, Dr Martine Keenan, also recognised with the Women in International Business Award at the same ceremony.

PharmAust's wholly owned synthetic and medicinal chemistry subsidiary, Epichem, is set to further improve its bottom line after paying off the $750,000 loan from Export Finance Australia taken out to help finance the construction of a state-of-the-art laboratory in 2015. This laboratory fuelled growth over the period from 2015 to 2018, with revenues increasing 38% to $3 million in the 2018 financial year.

PharmAust has received new data from Canada's BRI Biopharmaceutical Research that a specific combination of diet and excipient could double the amount of its Monepantel anti-cancer drug that can be delivered into the bloodstream of dogs. This could increase the flexibility for dosing schedules of Monepantel and potentially simplify the treatment of canine cancers.

ASX listed Biotech upstart PharmAust says that its ongoing clinical research in Melbourne is demonstrating that its anti-cancer drug, Monepantel's principle end-product, metabolite Monepantel Sulfone, retains the same biological activity as the drug itself. The metabolite shows little side effects upon healthy, non-cancerous cells and works together with Monepantel, producing a “double kick” in eliminating cancer cells. Reduced dosing treatments are envisaged for upcoming canine and human trials.

ASX listed biotech PharmAust now has sufficient data from testing of different tablet prototypes of its flagship Monepantel anti-cancer drug to take the best performing and most economical tablet for GMP manufacturing. The selected tablets will be used in formal dose escalation studies in healthy Beagle dogs to determine the maximum dose that can be given and with what safety margin.

Perth-based Epichem, a wholly owned subsidiary of ASX-listed biotech PharmAust, has received a contract extension with a leading US biotechnology company, Unity Biotechnology. The new contract, worth around US$1.65 million out to 2020, means Epichem will continue to provide synthetic and medicinal chemistry expertise to support Unity's drug discovery projects.

ASX-listed biotech PharmAust, has successfully reformulated its promising anti-cancer drug “Monepantel”. Perth-based PharmAust says the new form of Monepantel, which now takes the form of dry tablets, improves the drug's taste and meets dosage requirements, paving the way for trials in dogs expected to take place by the end of the year ahead of human clinical trials.

ASX listed PharmAust's wholly owned subsidiary Epichem has posted a record monthly revenue result for January. Pharmaust is developing a promising anti-cancer drug known as “Monepantel” at the Perth based Epichem facility that also undertakes contract work for some of the worlds leading pharmaceutical companies

ASX listed PharmAust has revealed a timetable for the development of its promising anti-cancer drug as the Perth-based company moves ahead with human and canine trials. After pleasing results in Phase I human tests of its “Monepantel” drug, the company is pushing ahead with Phase II canine trials.

Upstart biotech company Pharmaust is getting close to proving up their breakthrough anti-cancer drug in dogs with a second canine patient suffering from late stage cancer recruited last week. The company recently announced that a second dog had started treatment at Sydney's Animal Referral Hospital using PharmAust's reformulated drug known as Monepantel.

The University of Cambridge has begun a second phase of canine trials of PharmAust's promising anti-cancer drug, taking it a step closer to widespread availability for pet owners. The trial will also provide information on the potential for the Perth-based company's new drug as a breakthrough cancer treatment for humans.

ASX listed biotech company PharmAust today announced that a leading veterinary specialist would conduct more canine trials with its promising anti-cancer drug "MP"L. NSW-based dog cancer specialist, Dr Angela Frimberger, will evaluate MPL either as a monotherapy or in conjunction with chemotherapy in dogs that have not responded to standard cancer treatments.

ASX listed cancer drug hopeful Pharmaust have secured additional IP rights to their highly promising anti-cancer drug Monepantel by partially trading off rights to another project under their control. Under the new deal, Pharmaust will receive the remainder of the IP rights to Monepantel that were never transferred to them by the University of NSW.

Anti cancer specialist drug developer Pharmaust, has successfully altered the taste of their promising new anti-cancer drug known as Monepantel to make it taste better on the eve of a new trial of the drug in dogs. The trial will commence immediately at The University of Cambridge who were responsible for inventing the jet engine and identifying the structure of DNA.

Perth based Pharmaust has received a $250k Federal grant to conduct a research program into a little known illness known as Leishmaniasis disease. They will work in partnership with a Swiss not for profit who will retain rights to any drugs produced for humans with Pharmaust retaining the rights to any drugs developed that cure Leishmaniasis in animals.

Leading ASX listed Cancer drug specialist Pharmaust, are in discussions with a UK-based clinical oncologist to evaluate their anti-cancer drug known as Monepantel in patients with oesophageal cancer. The trials, which will analyse the effect of Monepantel on patient's tumours are designed to provide short term feedback on the efficacy of the drug.

Perth based listed cancer drug hopeful Pharmaust, has received a $546 000 Government windfall from the Research and Development Rebate Scheme. Under the scheme, eligible Australian companies that are undertaking approved research and development activities can claim up to 43.5% of their expenditure back from the Federal Government.

Anti-cancer drug hopeful Pharmaust has moved to overcome a limitation discovered in its promising cancer drug known as Monepantel during recent phase 1 human trials. Juniper Pharmaceuticals have been appointed to reformulate the company's Monepantel drug with the goal being to improve its taste and palatability.

PharmAust Limited has announced that its wholly-owned subsidiary Epichem Pty Ltd has been awarded a two-year extension to its current contract with Drugs for Neglected Diseases Initiative (DNDi)

Anti cancer drug hopeful Pharmaust has appointed expert medical research company GenScript to take the trialling of their exciting anticancer drug PPL-1 to the next level. GenScript will trial the company's PPL-1 drug in animals in conjunction with standard care drugs that are usually prescribed for each particular type of cancer. The company is looking to ensure there is no adverse reaction when mixing their drug with others,

ASX listed Pharmaust is starting to look really interesting following the completion a “first in human trial” of its PPL-1 ant-cancer drug sometimes known as Monepantel.

New anti-cancer lab to lead the fight for anti-cancer drugs in Perth.

“First in man” anti-cancer drug trial shows promising results